Valuing Early-Stage Life Sciences Companies: The Why, the How, and the Impact
Valuing early-stage life sciences companies can be complex. Because product development can take several years and be capital intensive, obtaining an accurate valuation is essential to align management’s, the shareholders’, and current and potential investors’ understanding of estimated value.
Verily & Samsung Team Up to Bring Smartwatch Data into Clinical Trials
Verily and Samsung are partnering to integrate data from Galaxy smartwatches into Verily’s Pre platform. The goal is to create an end-to-end system that pharma researchers can use to deploy wearable devices in studies, analyze patient data remotely and then interpret the results.
Eight Sleep Raises $50M to Build Predictive AI for Sleep
Eight Sleep's $50 million raise was led by Tether Investments. In total, Eight Sleep has raised over $250 million, and this round brings the company’s valuation to $1.5 billion.
Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision
GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concerns from U.S. and European regulators.
HIPAA Was Built for an Analog Era, Healthcare AI Has Outgrown It
Healthcare AI in the U.S. has progressed to a point where traditional, HIPAA-style compliance alone is no longer adequate. The next phase of regulation and market expectation will require continuous, medical-grade AI governance, and companies that don’t adapt now will be left behind.